Treatment with the aforementioned inhibitors as single agents demonstrated cytotoxicity, decrease of tumor cell motility, radiosensitization, antiproliferative effects, and degradation of HSP90 client proteins such as EGFRvIII [138,139,140,141,142]. The gene discussed is HSP90AA1; the disease is neoplasm.